VYNE Yarrow Bioscience, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
VYNE revenue and earnings
- Quarter ended Jun 30, 2026: revenue $97.0K, net income −$3.01M, EPS -3.51
- Quarter ended Mar 31, 2026: revenue $86.0K, net income −$3.59M, EPS -0.08
- Quarter ended Jun 30, 2025: revenue $69.0K, net income −$5.76M, EPS -6.73
- Quarter ended Mar 31, 2025: revenue $202K, net income −$8.61M, EPS -0.20
Recent VYNE insider trades
- Jan 15, 2025: Lepore Patrick G bought 15,000 shares ($43.8K)
5%+ owners
- Logos Global Management LP: 10.7% (Schedule 13G/A, filed Aug 7, 2026)
- Bellevue Group AG: 10.6% (Schedule 13G, filed Oct 7, 2026)
- JANUS HENDERSON GROUP Ltd.: 10.0% (Schedule 13G, filed Aug 7, 2026)
- Perceptive Advisors LLC: 10.0% (Schedule 13G, filed Aug 3, 2026)
- RTW Fund Group GP, LLC: 10.0% (Schedule 13G, filed Jul 30, 2026)
- venBio Global Strategic Fund V, L.P.: 10.0% (Schedule 13G, filed Aug 14, 2026)
Are insiders buying or selling VYNE?
No open-market insider buys or sells of Yarrow Bioscience, Inc. were reported in the last 12 months.
What was VYNE's revenue last quarter?
Yarrow Bioscience, Inc. reported revenue of $97.0K for the quarter ended June 30, 2026, with net income of −$3.01M.